- Home
- VIR vs DBD Comparison
VIR vs DBD Comparison
Compare VIR & DBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIR
- DBD
- Stock Information
- Founded
- VIR 2016
- DBD 1859
- Country
- VIR United States
- DBD United States
- Employees
- VIR N/A
- DBD N/A
- Industry
- VIR Biotechnology: Pharmaceutical Preparations
- DBD EDP Services
- Sector
- VIR Health Care
- DBD Technology
- Exchange
- VIR Nasdaq
- DBD Nasdaq
- Market Cap
- VIR 844.9M
- DBD N/A
- IPO Year
- VIR 2019
- DBD N/A
- Fundamental
- Price
- VIR $5.41
- DBD $46.37
- Analyst Decision
- VIR Strong Buy
- DBD Strong Buy
- Analyst Count
- VIR 7
- DBD 2
- Target Price
- VIR $33.57
- DBD $65.00
- AVG Volume (30 Days)
- VIR 1.0M
- DBD 149.8K
- Earning Date
- VIR 05-07-2025
- DBD 05-07-2025
- Dividend Yield
- VIR N/A
- DBD N/A
- EPS Growth
- VIR N/A
- DBD N/A
- EPS
- VIR N/A
- DBD N/A
- Revenue
- VIR $20,861,000.00
- DBD $3,696,800,000.00
- Revenue This Year
- VIR N/A
- DBD $1.70
- Revenue Next Year
- VIR $10.65
- DBD $1.89
- P/E Ratio
- VIR N/A
- DBD N/A
- Revenue Growth
- VIR N/A
- DBD N/A
- 52 Week Low
- VIR $4.95
- DBD $34.38
- 52 Week High
- VIR $14.45
- DBD $51.81
- Technical
- Relative Strength Index (RSI)
- VIR 35.98
- DBD 61.13
- Support Level
- VIR $5.83
- DBD $43.61
- Resistance Level
- VIR $6.29
- DBD $46.64
- Average True Range (ATR)
- VIR 0.31
- DBD 1.43
- MACD
- VIR 0.02
- DBD 0.31
- Stochastic Oscillator
- VIR 28.80
- DBD 95.53
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.